Status:

UNKNOWN

Safety and Efficacy of the Apexum Ablator

Lead Sponsor:

Apexum Ltd.

Collaborating Sponsors:

Monitoring: Quail CRO, Romania

Medistat Ltd., Israel

Conditions:

Periapical Periodontitis

Eligibility:

All Genders

18+ years

Phase:

NA

Brief Summary

The study is designed to test the hypothesis that there is a difference in healing kinetics and healing rate between teeth treated by conventional endodontic procedure alone and those in which such pr...

Detailed Description

Periapical lesions consist of inflammatory tissue replacing the bone surrounding the root-tip (apex) and are caused by bacteria present in an infected root canal (Metzger 2000). Endodontic (root canal...

Eligibility Criteria

Inclusion

  • Subject is \> 18 years old
  • Subject has periapical lesion(s) associated with root canal infection in one or more roots that have a single root canal per root. These may include upper and lower single rooted incisors, canines or premolars, as well as roots of multi-rooted teeth, providing that they have a single root canal per root. These may include distal roots of lower molars, palatal and disto-buccal roots of upper molars
  • Lesion mean diameter: 3-6 mm, PAI score 4 or 5
  • Roots with mature fully formed apices

Exclusion

  • Previous root canal filling
  • Roots with abnormal root canal morphology
  • Roots with more than one root canal per root, as either evident from the pre-operative radiographs or as discovered during initiation of the root canal treatment
  • A tooth that remained symptomatic after the first and when needed a second session of the root canal treatment (remained with an excessive sensitivity to percussion, persistent sinus tract, persistent exudate in the root canal etc.)
  • Un-restorable teeth
  • Significant periodontal pockets
  • Lack of cortical bone around the lesion, as judged clinically
  • Active acute infection - cellulites, abcess
  • Proximity of anatomical structures to the periapical lesion to the extent that Apexum Ablator enucleation procedure may damage or otherwise jeopardize these structures. Such anatomical structures may include the maxillary sinus, the nasal cavity, the inferior alveolar nerve and its canal, the mental nerve or any other structure that may be jeopardized by the procedure
  • Subject with:
  • Uncontrolled systemic hypertension
  • Severe uncontrolled Diabetes Mellitus
  • Current steroid therapy in excess of prednisone 5 mg/day
  • Chronic inflammatory oral disease
  • HIV positive patients
  • Chronic renal failure
  • Hematological disease (malignancy, severe anemia, bleeding tendency etc.)
  • Osteoporosis, receiving biphosphonates
  • Post head and neck irradiation treatment
  • In need of endocarditis antibiotic prophylactic treatment \[sub acute bacterial endocarditis (SBE\]
  • Other severe or life-threatening systemic disease (ASA P3 and above)

Key Trial Info

Start Date :

October 1 2006

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

Estimated Enrollment :

100 Patients enrolled

Trial Details

Trial ID

NCT00762840

Start Date

October 1 2006

Last Update

June 5 2009

Active Locations (2)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (2 locations)

1

Titu Maiorescu University

Bucharest, Romania

2

Cabinet Stomatologic Dr Dan Dragomirescu

Timișoara, Romania